Researchers at King Abdul-Aziz University Have Reported New Data on Bone Research (Engineered nanomedicine for myeloma and bone microenvironment targeting)
By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Bone Research are discussed in a new report. According to news originating from Jeddah, Saudi Arabia, by NewsRx correspondents, research stated, "Bone is a favorable microenvironment for tumor growth and a frequent destination for metastatic cancer cells. Targeting cancers within the bone marrow remains a crucial oncologic challenge due to issues of drug availability and microenvironment-induced resistance."
Our news journalists obtained a quote from the research from King Abdul-Aziz University, "Herein, we engineered bone-homing polymeric nanoparticles (NPs) for spatiotemporally controlled delivery of therapeutics to bone, which diminish off-target effects and increase local drug concentrations. The NPs consist of poly(D,L-lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), and bisphosphonate (or alendronate, a targeting ligand). The engineered NPs were formulated by blending varying ratios of the synthesized polymers: PLGA-b-PEG and alendronate-conjugated polymer PLGA-b-PEG-Ald, which ensured long circulation and targeting capabilities, respectively. The bone-binding ability of Ald-PEG-PLGA NPs was investigated by hydroxyapatite binding assays and ex vivo imaging of adherence to bone fragments. In vivo bio-distribution of fluorescently labeled NPs showed higher retention, accumulation, and bone homing of targeted Ald-PEG-PLGA NPs, compared with nontargeted PEG-PLGA NPs. A library of bortezomib-loaded NPs (bone-targeted Ald-Bort-NPs and nontargeted Bort-NPs) were developed and screened for optimal physiochemical properties, drug loading, and release profiles. Ald-Bort-NPs were tested for efficacy in mouse models of multiple myeloma (MM). Results demonstrated significantly enhanced survival and decreased tumor burden in mice pretreated with Ald-Bort-NPs versus Ald-Empty-NPs (no drug) or the free drug. We also observed that bortezomib, as a pretreatment regimen, modified the bone microenvironment and enhanced bone strength and volume."
According to the news editors, the research concluded: "Our findings suggest that NP-based anticancer therapies with bone-targeting specificity comprise a clinically relevant method of drug delivery that can inhibit tumor progression in MM."
For more information on this research see: Engineered nanomedicine for myeloma and bone microenvironment targeting. Proceedings of the National Academy of Sciences of the United States of America, 2014;111(28):10287-10292. Proceedings of the National Academy of Sciences of the United States of America can be contacted at: Natl Acad Sciences, 2101 Constitution Ave NW, Washington, DC 20418, USA. (National Academy of Sciences - www.nasonline.org/; Proceedings of the National Academy of Sciences of the United States of America - www.nasonline.org/publications/pnas/)
The news correspondents report that additional information may be obtained from A. Swami, King Abdulaziz Univ, Jeddah 21413, Saudi Arabia. Additional authors for this research include M.R. Reagan, P. Basto, Y. Mishima, N. Kamaly, S. Glavey, S.F. Zhang, M. Moschetta, D. Seevaratnam, Y. Zhang, J.H. Liu, M. Memarzadeh, J. Wu, S. Manier, J.J. Shi, N. Bertrand, Z.N. Lu, K. Nagano, R. Baron, A. Sacco and Roccaro (see also Bone Research).
Keywords for this news article include: Asia, Jeddah, Myeloma, Hematology, Engineering, Saudi Arabia, Bone Research
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC